Cost effectiveness of antimicrobial catheters in the intensive care unit: Addressing uncertainty in the decision by Halton, Kate et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
QUT Digital Repository:  
http://eprints.qut.edu.au/ 
Halton, Kate and Cook, David and Whitby, Michael and Paterson, David and Graves, 
Nicholas (2009) Cost effectiveness of antimicrobial catheters in the intensive care unit: 
Addressing uncertainty in the decision. Critical Care (Print), 13(2). 
 
          © 2009 Halton et al.; licensee BioMed Central Ltd. 
1
Cost-effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in
the decision
Kate A Halton1,2, David A Cook3, Michael Whitby4, David L Paterson1,5, and Nicholas Graves1,2
1 The Centre for Healthcare Related Infection Surveillance & Prevention, GPO Box 48, Brisbane,
Queensland, 4001 Australia
2 Institute of Health & Biomedical Innovation, Queensland University of Technology, 60 Musk
Avenue, Kelvin Grove, Queensland, 4059 Australia
3 Intensive Care Unit, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Queensland,
4102 Australia
4 Infection Management Services, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba,
Queensland, 4102 Australia
5 University of Queensland, Royal Brisbane & Women’s Hospital, Butterfield Street, Herston,
Queensland, 4029 Australia
Corresponding author: Kate Halton, k.halton@qut.edu.au
2
Abstract
Introduction: Some types of antimicrobial-coated central venous catheters (A-CVC) have been shown
to be cost-effective in preventing catheter-related bloodstream infection (CR-BSI). However, not all
types have been evaluated, and there are concerns over the quality and usefulness of these earlier
studies. There is uncertainty amongst clinicians over which, if any, antimicrobial-coated central venous
catheters to use. We re-evaluated the cost-effectiveness of all commercially available antimicrobial-
coated central venous catheters for prevention of catheter-related bloodstream infection in adult
intensive care unit (ICU) patients.
Methods: We used a Markov decision model to compare the cost-effectiveness of antimicrobial-coated
central venous catheters relative to uncoated catheters. Four catheter types were evaluated; minocycline
and rifampicin (MR)-coated catheters; silver, platinum and carbon (SPC)-impregnated catheters; and
two chlorhexidine and silver sulfadiazine-coated catheters, one coated on the external surface (CH/SSD
(ext)) and the other coated on both surfaces (CH/SSD (int/ext)). The incremental cost per quality-
adjusted life-year gained and the expected net monetary benefits were estimated for each. Uncertainty
arising from data estimates, data quality and heterogeneity was explored in sensitivity analyses.
Results: The baseline analysis, with no consideration of uncertainty, indicated all four types of
antimicrobial-coated central venous catheters were cost-saving relative to uncoated catheters.
Minocycline and rifampicin-coated catheters prevented 15 infections per 1,000 catheters and generated
the greatest health benefits, 1.6 quality-adjusted life-years, and cost-savings, AUD $130,289. After
considering uncertainty in the current evidence, the minocycline and rifampicin-coated catheters
returned the highest incremental monetary net benefits of $948 per catheter; but there was a 62%
probability of error in this conclusion. Although the minocycline and rifampicin-coated catheters had
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the highest monetary net benefits across multiple scenarios, the decision was always associated with
high uncertainty.
Conclusions: Current evidence suggests that the cost-effectiveness of using antimicrobial-coated
central venous catheters within the ICU is highly uncertain. Policies to prevent catheter-related
bloodstream infection amongst ICU patients should consider the cost-effectiveness of competing
interventions in the light of this uncertainty. Decision makers would do well to consider the current
gaps in knowledge and the complexity of producing good quality evidence in this area.
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Introduction
Catheter-related bloodstream infections (CR-BSI) increase health costs and patient morbidity [1], and
their prevention has been the target of national initiatives to create safer and more efficient healthcare
systems [2, 3]. These healthcare-acquired infections are among the group for which the US Centers for
Medicare and Medicaid Services are now able to withhold payments [4], thereby shifting the cost onto
the hospitals rather than healthcare payers who reimburse the clinical facilities. Given this change in
the economic context for infection control, decision makers are likely to pay more attention to the cost-
effectiveness of interventions they employ to reduce rates of CR-BSI [5].
The use of specific types of antimicrobial-coated central venous catheter (A-CVCs) to prevent CR-BSI
has been shown in earlier economic evaluations to be cost-saving and generate health benefits within
the wider healthcare system [6, 7]. However, not all have been evaluated and there are concerns over
the quality of these evaluations and the usefulness of their findings for real world decision making [8].
Problems with the existing economic evidence contribute to the ongoing uncertainty about the use of
A-CVCs. First, the relative cost-effectiveness of the different types of A-CVC is unknown as none of
the previous evaluations compared all available types. Second, recent epidemiological evidence [1]
suggests earlier evaluations may have overestimated the attributable mortality and length of stay
associated with CR-BSI, and these were key drivers of the results [8]. Third, the excess length of stay
due to infection is a major source of cost savings and the dollar value given to each bed-day released
will depend on the preferences of the decision maker. They cannot be directly observed and require
careful elicitation, and the valuation may change depending on who is making the decision. To date
there has been no discussion as to how these value judgments are derived, creating another subtle
source of uncertainty in the results of the earlier evaluations.
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There is continued uncertainty among clinicians over which, if any, A-CVC to use. Clinical guidelines
recommend their use only in specific circumstances [9], and evidence suggest that the uptake of these
technologies remains patchy [10, 11]. The purpose of this study is to evaluate the cost-effectiveness of
adopting A-CVCs to prevent CR-BSI in Australian ICUs. We consider all available catheter types, use
updated estimates of the consequences of infection, and explore how uncertainty can impact the
adoption decision. In doing so, we provide a deeper analysis of this infection control decision that will
support those working in this clinical area.
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Materials and methods
We undertook an economic evaluation to identify the cost-effectiveness of triple-lumen A-CVCs for
standard use in Australian adult ICUs. We considered all commercially manufactured A-CVCs sold in
Australia: minocycline and rifampicin (MR)-coated catheters; silver, platinum and carbon (SPC)-
impregnated catheters; and two chlorhexidine and silver sulfadiazine-coated catheters, one coated on
the external surface (CH/SSD (ext)) and the other coated on both catheter surfaces(CH/SSD (int/ext)).
The baseline comparator was uncoated polyurethane catheters.
Model development
Clinical events used to structure the model were identified in conjunction with intensive care clinicians.
Clinical and economic events under a healthcare perspective were identified and organised into Markov
states (Figure 1). Patients were assumed to receive a CVC on entry to ICU, and over subsequent daily
cycles either retained their catheter, had it removed, or developed a CR-BSI [12]. Patients faced an
underlying risk of mortality whilst in ICU and a further risk should they develop CR-BSI. The
surviving cohort was modeled for the remainder of their lifetime in monthly cycles, moving to yearly
cycles one year after discharge.
ICUs were assumed to have existing optimal infection control procedures in place. Multiple
catheterisations, catheters inserted or removed outside the ICU and future catheterisations were
excluded. We did not model catheter colonization, as this event alone carries no health or economic
consequences; or anaphylactic reaction to the CH/SSD catheters [13], as this event is rare. The
effectiveness of all catheters and the consequences of CR-BSI were considered independent of patient
age or disease severity and causative micro-organisms. Treatment success was considered to be final
and we did not model recurrence of infection. Economic costs were measured in 2006 Australian
dollars and health outcomes in quality-adjusted life-years (QALYs). Costs and health outcomes relating
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to the original ICU experience but occurring in future time periods were discounted at a rate of 3%. In
line with recommendations [14] we did not attempt to model future access to healthcare.
Framework for evaluation
The strong evidence that CR-BSI increases of length of stay in ICU and general wards suggests that
health care costs will vary between catheters if they differ in effectiveness at preventing infection.
Conversely, there is relatively weak evidence for the causal relationship between CR-BSI and
mortality; this implies a tenuous difference in health outcomes for different catheter choices. One
approach is to assume that health outcomes (measured in QALYs) are the same for all catheter types
and so economic evaluation could be simplified to a cost-minimization analysis. This approach to
making decision is, however, unhelpful [15]. Studies have not shown an absence of effect; rather they
have been unable to show a statistically significant positive effect, between CR-BSI and mortality. The
best interpretation is that we are uncertain about any relationship between CR-BSI and mortality. Thus
we chose to use cost-effectiveness analysis (CEA) and explore the impact of the uncertainty about
attributable mortality (and other model parameters) on our conclusions.
Data sources
Parameters used in the model are shown in Table 1. Where estimates were obtained from the literature,
relevant articles were identified via reproducible searches in the Medline database to 1 January 2008,
and earlier economic evaluations of strategies to prevent CR-BSI were reviewed. Bibliographic details
for all relevant studies identified in these searches are provided in Additional data file 1.
ICU population
The context of the evaluation was a Level 3 (tertiary referral) ICU [16]. Based on a four year dataset of
11,790 ICU admissions we assumed that 17% would receive a CVC (Mullaney D. Use of variables
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immediately prior to ICU admission to determine short term outcomes and assess ICU performance
after cardiac surgery. Second International Conference on Quality Audit and Outcomes Research in
Intensive Care; 2008. Christchurch, New Zealand). This catheterized cohort had a mean age of 62.7
(s.d. 17.2) years, mean Acute Physiology and Chronic Health Evaluation II score 17.1 (s.d. 8) and 65%
were male. These estimates are comparable to those reported for 46 publicly funded ICUs by the
Australia New Zealand Intensive Care Society [17]. Baseline risk of ICU mortality was 9.8% and
16.1% by hospital discharge.
CR-BSI & A-CVCs
Probability of CR-BSI was modeled as increasing, in stepwise increments, with duration of
catheterization [18] to give an overall incidence of infection of 2.5%. This was observed in routine
surveillance data collected from February 2001 to December 2005 in 21 medium-to-large public
hospitals in Queensland, Australia [19]. Estimates for the effectiveness of each type of A-CVC were
taken from a single systematic review, chosen from amongst fourteen identified because it provided
relative risks separately for each type of coating [20].
Consequences of CR-BSI
The relative risk of hospital mortality associated with CR-BSI was estimated to be 1.06 [1]. Given a
9.8% baseline risk this corresponds to an absolute increase in mortality just under 1%. Excess length of
stay due to infection was estimated at 2.4 ICU and 7.5 general ward days [21]. These values were
chosen from amongst nineteen estimates of attributable mortality and eleven estimates of increases to
length of stay identified in a literature search, as they were of high quality (judgment based on Samore
& Harbarth [22]) and the population was comparable to our ICU context.
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Health outcomes
Annual mortality rates for fifteen years post-ICU discharge were taken from a data linkage study [23]
that followed over 10,000 Australian ICU patients. Subsequent life expectancy was based on Australian
Institute of Health and Welfare published age-specific mortality rates [24]. To calculate QALYs,
preference based utility weights were assigned to cycles spent in the ICU and 6 months immediately
post-discharge. Although evidence suggests that quality of life may be reduced in some survivors for a
longer period post-discharge [25], information on this was unavailable for our population, so, to be
conservative, life expectancy for those surviving beyond this period were adjusted using Australian
population quality of life norms [26]. Fourteen studies estimated utility weights for ICU patients.
Values were used from the study [27] with participant demographics most similar to our cohort. This
study used an instrument (i.e. the EQ-5D) shown to predict weights similar to the Australian Quality of
Life instrument used to derive population norms [28]. No further quality of life decrement was
attributed to CR-BSI.
Costs
All costs were valued at 2006 prices, using the Bureau of Labor Statistics Consumer Price Index [29] to
adjust where necessary. Consumable costs in the evaluation included the price of a catheter, diagnosis
costs of one catheter tip and two blood cultures per CR-BSI and treatment costs. Treatment costs were
a weighted average of the cost of standard regimens for causative organisms observed within the
surveillance system: two weeks Vancomycin, ten days Ticarcillin, four weeks Fluconazole. Prices for
all consumables reflect those faced by Queensland Health decision makers.
The economic value of bed-days released by the prevention of CR-BSI was assessed from two alternate
perspectives. A broader perspective of the healthcare decision maker who manages waiting lists, and
for whom there is a real economic benefit in releasing a bed-day for another patient to occupy, and a
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narrower perspective of a manager working within an ICU or hospital. Values to represent the broader
perspective were obtained for an ICU bed-day from a detailed costing study of an Australian ICU [30]
and for a general ward bed-day from an earlier economic evaluation which considered spending
patterns for Australian public hospital services [31]. These estimates of $3,021 and $843 represent
short-run average costs calculated by dividing total costs (i.e. fixed and variable costs) by the total bed
days for a 12 month budget period. They may or may not approximate the economic opportunity cost
of losing a bed-day to CR-BSI. The alternate narrow perspective value considered only the variable
cost per bed-day. Variable costs are the cash savings that budget holders within the hospital can recoup
if bed-days are not used; they include items such as fluids, dressings and pharmaceuticals. These costs
are meaningful to hospital administrators who cannot avoid fixed operating costs, even if infections
reduce [32]. An important caveat for the narrow perspective costs is that they decrease over the
duration of ICU stay [33]; we assumed it would be later, less costly, days released by preventing
infection and adjusted our baseline estimates based on the daily pattern of variable costs reported in a
similar patient population [33], to give estimates of AUD $362 ICU and AUD $101 general ward.
Model evaluation
Model evaluation was done in three stages. First uncertainty in the cost-effectiveness evaluation was
ignored and a single value was used for each model parameter. The incremental change in costs (∆C)
and QALYs (∆E) were estimated for each type of A-CVC and incremental cost-effectiveness ratios
(ICERs) were calculated (∆C / ∆E). A catheter type was considered cost-saving if greater health
benefits and reduced costs were achieved as compared to uncoated catheters, and considered cost-
effective if the ICER was below a threshold willingness-to-pay ratio (λ) of AUD $40,000 per QALY.
This threshold was chosen based on an analysis of positive reimbursement decisions made by the
Pharmaceutical Benefits Advisory Committee, Australia [34]
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Second, probabilistic sensitivity analysis (PSA) [35] was used to capture uncertainty in the current data.
The error in each estimate (parameter) used in the model, as described by its standard error, was
characterized using an appropriate probability distribution (Table 1), except costs which were assumed
known in the context of the evaluation. Ten thousand Monte Carlo simulations were run; in each one a
new value was drawn for each parameter from within the distribution specified. The results of each
simulation were presented as the monetary net benefits generated by each catheter type. Monetary net
benefits were used as they are linear and have improved properties as compared to ICERs for decision
making [36]. Although we expressed net benefits in monetary terms this is not a cost-benefit analysis.
Monetary net benefits were calculated by valuing incremental QALYs generated by the A-CVC at
$40,000 each (the willingness-to-pay threshold) and then subtracting incremental costs (i.e. NB = (λ *
∆E) - ∆C).
The average monetary net benefit across the 10,000 simulations was calculated for each catheter type
along with 95% credible intervals. Given the economic objective of maximizing benefits given scarce
resources, the optimal decision was defined as the catheter associated with the highest average
monetary net benefit; choosing anything else would incur an opportunity cost. The likelihood of error
in this conclusion was also calculated. The proportion of simulations in which a catheter returned the
highest monetary net benefit represents the probability that catheter type is optimal; one minus this
proportion represents the probability that the catheter does not return the highest monetary net benefits,
but instead incur a cost, and the decision is incorrect. Table 2 illustrates this interpretation using
hypothetical data for two novel treatments compared to standard practice.
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Third we used scenario analysis to explore uncertainty introduced by the fact that some data used in the
model was of low quality. Using a modified version [37] of the potential hierarchies of data sources for
economic evaluations [38], we identified data of medium and low quality (Table 1); defined as scoring
level three or below. For each parameter with medium/low quality data we assigned a plausible
alternate value and re-evaluated the model. The dollar value given to the opportunity cost of bed-days
was changed to reflect the broader and narrower perspectives of different decision makers. A higher
estimate for attributable mortality of 15% was used, which is comparable to that assumed in earlier
economic evaluations of A-CVCs. Higher estimates of the extension to stay of 6.5 days on the ICU and
6 days on the general ward due to CR-BSI were used. All utility weights for health states were
removed, which is equivalent to using unadjusted life-years rather than QALYs. The final scenario
reflected the fact that the absolute effectiveness and cost-effectiveness of A-CVCs will be dependent on
starting rates of infection [39]; lower (0.8%) and higher (5.0%) rates were used to cover the range
reported from individual hospitals within the surveillance dataset. In each scenario we reran an analysis
to recalculate the monetary net benefit for each catheter type and so identify the optimal catheter.
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Results
The results of the first analysis, without uncertainty, showed all four types of A-CVC were cost-saving
relative to uncoated catheters (Figure 2). The antibiotic-coated catheter (MR) achieved the greatest
health benefits and lowest costs and dominated the use of uncoated and the three antiseptic-coated
catheter types (SPC, CH/SSD (ext) and CH/SSD (int/ext)). Compared to uncoated catheters, the use of
MR catheters avoided 15 infections and generated 1.6 QALYs per 1,000 catheters placed. The MR
catheters also released 32 ICU bed-days and 95 general ward bed-days and achieved cost-savings of
AUD $130,000 per 1,000 catheters (Table 3).
The second analysis based on PSA to incorporate uncertainty indicated that at a willingness-to-pay
threshold of $40,000 per QALY the average monetary net benefits estimated for each catheter type
were very similar with substantial overlap in the 95% credible intervals (Table 3). Figure 3 shows the
distribution of monetary net benefits for the MR, CH/SSD(ext) and uncoated catheters, for clarity the
other catheter types have been omitted as their distributions lie over those presented. The MR catheters
returned the highest monetary net benefits and represented the optimal choice given current
information. They are associated with expected incremental monetary net benefits of $948 per catheter
relative to retaining the uncoated type (i.e. the average monetary net benefits for a MR catheter,
$391,612, minus those for an uncoated catheter, $390,664), but the probability of error in this decision
is 62% (Table 4).
For the third analysis, using alternate scenarios for key parameters, the MR catheters maximized
monetary net benefits in all cases. However, the probability of error in this decision was consistently
high and the 95% credible intervals for the estimated monetary net benefits associated with these
catheters was large (Table 4). The lowest estimate of monetary net benefits arose when bed-days were
valued at variable cost savings only (i.e. the narrow hospital perspective). In this scenario, monetary net
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benefits associated with MR catheters would be just under $200 per catheter relative to uncoated
catheters because the catheters were no longer cost-saving instead requiring an increase in expenditure
to produce health benefits (Table 4). The highest estimate of monetary net benefits was obtained when
an attributable mortality of 15% was assumed. In this scenario, MR catheters were cost-saving and
generated high monetary net benefits of nearly $2,441 per catheter relative to retaining uncoated
catheters. Scenarios which returned higher estimates of expected monetary net benefits were associated
with less uncertainty. Under the high mortality scenario, the probability that choosing MR catheters as
optimal was incorrect fell to 46%, whilst in the low bed-days scenario, where expected monetary net
benefits were low, the error probability in this decision was 76%
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Discussion
Our evaluation suggests any decision regarding the use of A-CVCs in ICU patients is uncertain. The
findings from the first analysis, which do not consider uncertainty, concur with existing economic
evidence [6, 7]. This shows that, for all four types of antimicrobial catheter, health gains will be
accompanied by cost-savings. Given the assumption of a low attributable mortality and a low rate of
infection, expected health gains are minimal and the decision is driven by the change in costs. Most of
these costs represent the value of obtaining increased capacity within the ICU, rather than cash savings.
Nevertheless, the results of the first analysis imply a decision not to adopt these catheters will harm
patients, by reducing their health status and increasing their risk of mortality, and simultaneously,
waste resources within the healthcare system.
Our second analysis, using PSA, introduces the uncertainty associated with the decision. Based on
current information, the MR catheters are the optimal decision because they return the highest net
monetary benefits relative to all other catheter types. However, the probability of error in this
conclusion is high, 62%. Our third analysis shows that MR catheters remain the optimal decision across
a range of scenarios and quantifies how uncertainty in this decision varies. Uncertainty is lower for
scenarios where decision makers believe that attributable mortality is high, where they value bed-days
highly, or where the starting infection rate is high. This finding fits with conclusions from a recent
meta-analysis that suggests that antimicrobial catheters will return a higher treatment benefit when
infection rates are high [39], and provides support for current guidelines which recommend reserving
their use for settings with high infection rates [9]. However, even in these scenarios, the probability that
this conclusion is wrong, and the MR catheters are not optimal, does not reduce below 46%.
Interpreting the results of cost-effectiveness analyses under uncertainty requires decision makers to
think beyond conventional error rates as used in statistical analysis. Decision makers looking to
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maximize health returns from their budget, should choose between these catheters by selecting the
option with the highest monetary net benefits. Given the current evidence MR catheters should be
chosen even if the probability of error in this conclusion exceeds the standard level of 5% used to
define statistical significance. The justification is that a decision not to use them, in favour of uncoated
catheters, would impose economic costs, arising from average monetary net benefits foregone, of $948
per catheter [40] (i.e. $391,612 minus $390,664). This conclusion should lead to rapid and sustained
uptake of the technology [5], yet their use appears to be limited, despite earlier estimates of these
catheters being cost-effective [6, 7]. We suggest that uncertainty in this cost-effectiveness evidence
may be partly responsible.
Studies have shown that decision makers are heavily influenced by uncertainty [34, 41]. Presenting
decision makers with an estimate of uncertainty in the results of an economic evaluation is important
because: it makes the current state of knowledge about the decision explicit and quantifies confidence
(or lack of) in conclusions; it allows them to weigh the cost-effectiveness results against other relevant
considerations in the adoption decision including their own attitude to risk; and, it provides an
indication of the value of conducting further research to reduce uncertainty.
Two aspects to uncertainty are important; the probability of making the wrong choice and the potential
consequences of getting it wrong. Both elements are required; a decision with a 5% probability of
being wrong may still be perceived as uncertain if the consequences are very large. Decision makers
tend to be risk averse. Rather than being focused solely on maximizing health returns, they are also
concerned with interventions that have the potential to result in harmful outcomes. If there is no
potential for harm then decision makers may be happy to accept a new intervention with a high but
uncertain benefit, but where the potential for harm is perceived to be high, an existing intervention with
a lower benefit may be preferred. Antimicrobial catheters are perceived to carry a risk of a number of
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negative outcomes that are likely to deter from their introduction, including the potential for a loss of
focus on hygiene procedures. There has also been discussion [42] that MR catheters may select for
resistant organisms, with higher morbidity and costs [43]. This negative could outweigh potential short-
term benefits from these catheters [44]. An absence of clear evidence [45] makes it difficult to
quantitatively incorporate this risk into an economic evaluation [46] but it is an important consideration
in the adoption decision.
Decision makers deciding whether to use antimicrobial catheters also have a second choice; whether to
collect more information to reduce uncertainty in their choice [47]. Value of information analysis [40]
can be used to estimate the expected monetary net benefits arising from collecting new information and
compare this to the anticipated research costs to indicate whether the research is justifiable. It has been
suggested further trials of antimicrobial catheters should be undertaken [42]. Due to the relative rarity
of infection these will require a large sample size and the involvement of multiple institutions [42],
making them an expensive proposition. Estimating the expected monetary net benefits from a trial
would indicate if this is the best way to spend research dollars.
Some important sources of uncertainty have been explored in these analyses; but there are other
uncertain elements in this decision which have not been explicitly examined. There is evidence the
relative effectiveness of A-CVCs, as compared to uncoated catheters, varies according to duration of
catheterization [48] and causative organism [49] and there have been reports of toxicity associated with
use of particular types of catheter [13]. However, a lack of data about these concerns both generally,
and in relation to each specific coating, meant we were unable to model their impact. If these aspects
reduce the effectiveness of any of the catheter types then its cost-effectiveness would also be reduced.
Alternatively there may be specific subgroups of patients for whom the cost-effectiveness of these
catheters can be determined with greater certainty. We did not test assumptions about life expectancy
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and quality of life in ICU survivors, although these will not alter conclusions about which catheter is
optimal as all types will be affected equally.
This evaluation, like those reported in earlier studies, is based on a simplified version of a complex
decision. It did not include intangible benefits to reduced infection rates, including the increases to
clinical morale and public confidence in the healthcare system demonstrated by the national campaigns
to reduce rates of CR-BSI [2] and forming part of the rationale for the introduction of the Deficit
Reduction Act [4]. Decision makers often consider a wider range of outcomes when deciding on the
adoption of a new technology [34, 41] and clearly the economic value in reducing infection rates goes
beyond the capacity released within hospitals. Valuing these intangible outcomes may improve the
representation of the economics of preventing infection, but it would be difficult to achieve. It has been
suggested that MR-coated catheters are difficult to insert [6] making them unpopular amongst
clinicians but data comparing failure rates for insertion are not available in order to incorporate this
cost. Finally, recent research has shown that improving catheter care by intervention “Bundles” is a
highly effective way to reduce rates of CR-BSI [50]. In an evaluation comparing “Bundles” with
antimicrobial catheters it may be that the former would dominate. This is not evaluated here and
deserves rigorous exploration rather than hypothesizing.
Conclusions
Antimicrobial catheters have been available as a means of preventing CR-BSI in the ICU for two
decades. Although earlier studies have indicated these devices are cost-saving, the findings of this
evaluation represent a deeper analysis of the decision than previously available that will help decision-
makers in any setting considering adopting A-CVCs judge the cost-effectiveness of these devices. We
have shown that the cost-effectiveness of these catheters is uncertain, and are not surprised that
infection control decision makers are reticent about using antimicrobial catheters despite the economic
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evidence. Failure to consider uncertainty generates overly simplistic results and creates skepticism
amongst decision makers using them to guide infection control policy. Value of information analyses
may suggest where research to reduce this uncertainty should focus, but in the meantime, legislation
based on the economics of infection control would do well to consider the complexity of producing
good quality evidence in this area.
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Key Messages
• The cost-effectiveness of antimicrobial catheters to prevent catheter-related bloodstream infection
in the intensive care unit is highly uncertain.
• Estimates of cost-effectiveness which do not consider uncertainty indicate that minocycline &
rifampicin catheters generate the greatest health benefits, 1.6 quality-adjusted life-years, and
opportunity cost-savings, AUD $130,289 per 1,000 catheters placed relative to uncoated catheters.
• When uncertainty in information currently available to inform this decision is considered, MR-
coated catheters return the highest monetary net benefits relative to all other catheter types but there
is a 62% probability that this is incorrect.
• Value of information analyses may suggest where research to reduce uncertainty in this decision
should focus to achieve maximum benefit, but in the meantime, decision makers would do well to
consider the complexity of producing good quality evidence in this area.
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Figure Legends
Figure 1. Markov model used for the evaluation
Figure 2. Cost-effectiveness of antimicrobial central venous catheters in the baseline analysis
(results per 1,000 catheters)
CH/SSD (int/ext) = internally & externally coated chlorhexidine & silver sulfadiazine catheters
CH/SSD (ext) = externally coated chlorhexidine & silver sulfadiazine catheters
SPC = silver, platinum & carbon impregnated catheters
MR = minocycline & rifampicin coated catheters
QALY = quality-adjusted life year
Figure 3. Distribution of monetary net benefits associated with selected catheter types
CH/SSD (ext) = externally coated chlorhexidine & silver sulfadiazine catheters
MR = minocycline & rifampicin coated catheters
QALY = quality-adjusted life year
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Table 1. Parameter estimates used in the model
Parameters Baseline
estimate
Variation
(s.e.) Distribution Source
Level of
evidence
Infection related events
Probability of CR-BSI modeled in stepwise
increments – available on
request
beta database 1
RR mortality (CR-BSI) 1.06 0.18 lognormal [1] 2
Extra days in ICU 2.41 0.83 lognormal
Extra days on hospital ward 7.54 1.81 lognormal [21] 2
Effectiveness A-CVCs (RR)
SPC
CH/SSD (ext)
CH/SSD (int/ext)
MR
0.54
0.66
0.70
0.39
0.62
0.17
0.43
0.43
log
transformed
normal
[20] 1+
Baseline probabilities of mortality
ICU mortality 0.098 0.002 beta dataset 2
Hospital mortality 0.069 0.001 beta dataset 2
Annual
mortality
post-discharge
Year 1
Years 2-3
Years 4-5
Years 6-10
Years 11-15
0.050
0.027
0.028
0.037
0.042
0.002
0.002
0.002
0.003
0.003
beta [23] 2
Underlying
annual
mortality
45-64 yrs
65-84 yrs
85+ yrs
0.004
0.030
0.140
-
-
-
n/a [24] 1
Utilities
Utility ICU 0.66 0.27 beta [27] 3
Utilities
population
norms
50-59 yrs
60-69 yrs
70-79 yrs
80+ yrs
0.80
0.79
0.75
0.66
0.22
0.19
0.25
0.29
beta [26] 3
Costs, 2006 AUD
ICU bed-day 3021 - n/a [30] 4
Hospital bed-day 843 - n/a [31] 3
Diagnostics CR-BSI 101.70 - n/a database 1
Treatment CR-BSI 591.30 - n/a database 1
Additional cost
per catheter
SPC
CH/SSD (ext)
CH/SSD (int/ext)
MR
22.36
11.64
41.35
59.36
-
-
-
-
n/a database 1
Abbreviations: CR-BSI catheter related bloodstream infection; ICU intensive care unit; RR relative
risk; A-CVCs antimicrobial central venous catheters; SPC silver, platinum & carbon; CH/SSD
chlorhexidine silver sulfadiazine; int/ext internally & externally coated; MR minocycline & rifampicin.
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Table 2. Monetary net benefits for a hypothetical evaluation comparing two novel treatments to
standard practice
Standard
practice
Treatment
A
Treatment
B
Optimal choice
Simulation 1 140 150 160 B
Simulation 2 100 110 120 B
Simulation 3 110 100 100 Std
Simulation 4 100 150 130 A
Simulation 5 130 120 110 Std
Average expected NB 116 126 124 Std;A;B = 40%;20%;40%
Results are expressed as monetary net benefits, each simulation is equally likely to be “true”.
Treatment A is associated with the highest expected net benefit ($126), but because the distribution of
monetary net benefits is skewed, it is preferred in only 20% of samples. Treatment A is therefore
optimal, but the error probability associated with this choice is 80%. This probability is substantially
higher than the 5% used for tests of statistical significance. The choice to remain with standard practice
still carries a 40% probability of not returning the highest monetary net benefits and could be expected
to incur economic costs of $10 (i.e. $126 less $116). The alternative with the highest monetary net
benefit is the optimal decision, but that decision can be highly uncertain.
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Table 3. Economic evaluation of antimicrobial central venous catheters: incremental costs and
health outcomes under baseline analysis
Catheter
type
Infections
avoided+
ICU bed-
days
released+
Costs
saved+
(2006
AUD)
QALYs
gained+ ICER
Average monetary
net benefits*
(95% CI)
Uncoated
390,664
(371,984 - 408,416)
CH/SSD
(ext) 8.4 18.1 $93,281 0.91 dominated
391,212
(372736 - 408,687)
CH/SSD
(int/ext) 7.4 15.9 $51,126 0.80 dominated
391,030
(372,467 - 408,574)
SPC 11.4 24.6 $120,062 1.23 dominated
391,206
(372,687 - 408,772)
MR 15.2 32.8 $130,289 1.64 cost-
saving
391,612
(373,159 - 408,861)
+ results presented per 1,000 catheters
* monetary net benefits reported per catheter assuming a willingness-to-pay for a QALY of AUD
$40,000
Abbreviations: SPC silver, platinum & carbon; CH/SSD chlorhexidine silver sulfadiazine; int/ext
internally & externally coated; MR minocycline & rifampicin; AUD Australian dollars; ICU intensive
care unit; QALY quality-adjusted life year; ICER incremental cost-effectiveness ratio.
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Table 4. Optimal choice of catheter under uncertainty, given different data scenarios
Optimal catheter choice Incremental outcomes
with no uncertainty
Average monetary net
benefits given
uncertainty
(,000 dollars) *Scenario
Catheter
type
Probability
of error Costs+ QALYs+ Mean
95% credible
interval
Baseline MR 0.62 - $130,289 1.64 948 (-106, 3,792)
Low bed-day
($335 ICU / $101
ward)
MR 0.76 + $28,257 1.64 191 (-348, 1,317)
High mortality
(15%) MR 0.46 - $106,223 26.65 2,441 (116, 8,516)
No utility weights
used MR 0.62 - $130,289 2.33 1,042 (-166, 3,961)
Increased length of
stay (6.5d ICU / 6d
ward)
MR 0.56 - $282,038 1.64 1,239 (-57, 4,795)
Low infection rate
(0.8%) MR 0.75 - $1,972 0.53 325 (-71, 1,283)
High infection rate
(5.0%) MR 0.56 - $314,400 3.23 1,725 (-139, 6,455)
+relative to uncoated catheters and per 1,000 catheters
*monetary net benefits reported per catheter assuming a willingness-to-pay for a QALY of AUD
$40,000
ICU
patient
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CVC
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